CClinicalTrials.gg
Sign In
CompletedNCT00015249Updated Jan 12, 2017

Prepulse Inhibition of Startle in Cocaine Dependence - 7

A Phase 1 interventional study of Amantadine in Cocaine-Related Disorders and Substance-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA). Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by National Institute on Drug Abuse (NIDA) · Phase 1, Interventional, and Diagnostic

Phase
Phase 1
Study type
Interventional
Enrollment
0
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

Read the detailed description

The objective of this study is to assess the effects of chronic cocaine use on the acoustic startle response and on gating of this response in humans.

02

Conditions studied

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Keywords

  • cocaine dependence
03

In context

Cocaine-Related Disorders

415 studies on the registry are indexed under Cocaine-Related Disorders; 12 are open to participants now.

Browse Cocaine-Related Disorders studies →

Lead sponsor

National Institute on Drug Abuse (NIDA) is the lead sponsor of 388 studies on the registry; 19 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

Cocaine dependence. Male. Right handed. Negative urine for cocaine

Exclusion criteria

Exclusion Criteria:

Positive urine for cocaine. History of head trauma. Significant medical disease.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Masking
Double
Enrollment
0 participants

Interventions

  • DrugAmantadine
06

What researchers measure

Primary outcomes

  1. Percent prepulse inhibition

  2. Cocaine assessment

07

Study locations

1 site
  • New York MDRU
    New York, New York 10010, United States
08

References and documents

Publications

  • CPDD, 98, 99 NIDA Research Monograph Series 179, 1998 Manuscript submitted..
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00015249
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
New York MDRU
First posted
Apr 18, 2001
Start date
Feb 1997
Primary completion
Apr 1998
Completion
May 1998
Last update
Jan 12, 2017

Study contacts

John Rotrosen, M.D.
principal investigator · New York MDRU
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 1998. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cocaine-Related Disorders→

Other studies from this sponsor

National Institute on Drug Abuse (NIDA)

Start the discussion